Cargando…
Theranostic cells: emerging clinical applications of synthetic biology
Synthetic biology seeks to redesign biological systems to perform novel functions in a predictable manner. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranos...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261392/ https://www.ncbi.nlm.nih.gov/pubmed/34234299 http://dx.doi.org/10.1038/s41576-021-00383-3 |
_version_ | 1783719002149748736 |
---|---|
author | McNerney, Monica P. Doiron, Kailyn E. Ng, Tai L. Chang, Timothy Z. Silver, Pamela A. |
author_facet | McNerney, Monica P. Doiron, Kailyn E. Ng, Tai L. Chang, Timothy Z. Silver, Pamela A. |
author_sort | McNerney, Monica P. |
collection | PubMed |
description | Synthetic biology seeks to redesign biological systems to perform novel functions in a predictable manner. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex diseased states. Ex vivo and in vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer, microbiome dysbiosis and autoimmune and metabolic diseases. While probiotic therapies have advanced to clinical trials, chimeric antigen receptor (CAR) T cell therapies have received regulatory approval, exemplifying the clinical potential of cellular therapies. This Review discusses preclinical and clinical applications of bacterial and mammalian sensing and drug delivery platforms as well as the underlying biological designs that could enable new classes of cell diagnostics and therapeutics. Additionally, we describe challenges that must be overcome for more rapid and safer clinical use of engineered systems. |
format | Online Article Text |
id | pubmed-8261392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82613922021-07-07 Theranostic cells: emerging clinical applications of synthetic biology McNerney, Monica P. Doiron, Kailyn E. Ng, Tai L. Chang, Timothy Z. Silver, Pamela A. Nat Rev Genet Review Article Synthetic biology seeks to redesign biological systems to perform novel functions in a predictable manner. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex diseased states. Ex vivo and in vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer, microbiome dysbiosis and autoimmune and metabolic diseases. While probiotic therapies have advanced to clinical trials, chimeric antigen receptor (CAR) T cell therapies have received regulatory approval, exemplifying the clinical potential of cellular therapies. This Review discusses preclinical and clinical applications of bacterial and mammalian sensing and drug delivery platforms as well as the underlying biological designs that could enable new classes of cell diagnostics and therapeutics. Additionally, we describe challenges that must be overcome for more rapid and safer clinical use of engineered systems. Nature Publishing Group UK 2021-07-07 2021 /pmc/articles/PMC8261392/ /pubmed/34234299 http://dx.doi.org/10.1038/s41576-021-00383-3 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article McNerney, Monica P. Doiron, Kailyn E. Ng, Tai L. Chang, Timothy Z. Silver, Pamela A. Theranostic cells: emerging clinical applications of synthetic biology |
title | Theranostic cells: emerging clinical applications of synthetic biology |
title_full | Theranostic cells: emerging clinical applications of synthetic biology |
title_fullStr | Theranostic cells: emerging clinical applications of synthetic biology |
title_full_unstemmed | Theranostic cells: emerging clinical applications of synthetic biology |
title_short | Theranostic cells: emerging clinical applications of synthetic biology |
title_sort | theranostic cells: emerging clinical applications of synthetic biology |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261392/ https://www.ncbi.nlm.nih.gov/pubmed/34234299 http://dx.doi.org/10.1038/s41576-021-00383-3 |
work_keys_str_mv | AT mcnerneymonicap theranosticcellsemergingclinicalapplicationsofsyntheticbiology AT doironkailyne theranosticcellsemergingclinicalapplicationsofsyntheticbiology AT ngtail theranosticcellsemergingclinicalapplicationsofsyntheticbiology AT changtimothyz theranosticcellsemergingclinicalapplicationsofsyntheticbiology AT silverpamelaa theranosticcellsemergingclinicalapplicationsofsyntheticbiology |